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Abstract
The International vocabulary of metrology – Basic and general concepts and associated terms (VIM3, 2.26 measurement uncertainty, JCGM 
200:2012) defines uncertainty of measurement as a non-negative parameter characterizing the dispersion of the quantity values being attributed 
to a measurand, based on the information obtained from performing the measurement. Clinical Laboratory Standards Institute (CLSI) has published 
a very detailed guideline with a description of sources contributing to measurement uncertainty as well as different approaches for the calcula-
tion (Expression of measurement uncertainty in laboratory medicine; Approved Guideline, CLSI C51-A 2012). Many other national and internatio-
nal recommendations and original scientific papers about measurement uncertainty estimation have been published. In Croatia, the estimation of 
measurement uncertainty is obligatory for accredited medical laboratories. However, since national recommendations are currently not available, 
each of these laboratories uses a different approach in measurement uncertainty estimation. The main purpose of this document is to describe the 
minimal requirements for measurement uncertainty estimation. In such way, it will contribute to the harmonization of measurement uncertainty 
estimation, evaluation and reporting across laboratories in Croatia. This recommendation is issued by the joint Working group for uncertainty of me-
asurement of the Croatian Society for Medical Biochemistry and Laboratory Medicine and Croatian Chamber of Medical Biochemists. The document 
is based mainly on the recommendations of Australasian Association of Clinical Biochemists (AACB) Uncertainty of Measurement Working Group and 
is intended for all medical biochemistry laboratories in Croatia.
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Review
Introduction
Measurement uncertainty estimation results from 
the need for comparison of laboratory results. Ac-
cording to EN ISO 15189 (3.17.) uncertainty of meas-
urement is “a parameter associated with the result 
of a measurement that characterises the disper-
sion of the values that could reasonably be attrib-
uted to the measurand“ (1). It means that measure-
ment uncertainty gives us the range of values 
where we could expect a true value of the measur-
and (or a quantifiable property of the analyte) with 
the same probability. Further, one should not con-
sider measurement uncertainty as an indicator of 
the measurement system error but rather as a re-
sult of the variability of the measurement condi-
tions. Thus, it is the property of the measurement 
result. 
In the analytical process, the source of uncertainty 
could be any process, which contributes to uncer-
tainty of measurement result. The sources of un-
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certainty can be found in the preanalytical, analyt-
ical and postanalytical phase. Unfortunately, the 
sources of uncertainty in the preanalytical and 
postanalytical phase cannot be quantified. Thus, 
the estimation of measurement uncertainty can 
be done only for the analytical phase. 
Measurement uncertainty may be expressed as 
standard, relative, combined and expanded (2). 
Opposed to analytical chemistry laboratories, 
which always present measurement result with its 
uncertainty, in medical laboratories the estimated 
measurement uncertainty is not commonly ex-
pressed with measurement result on a laboratory 
report. However, the information on measurement 
uncertainty should be easily accessible to the us-
ers of laboratory services on demand. 
Estimation of measurement uncertainty and its 
periodical verification ensure that a laboratory 
meets defined quality specifications of the meth-
ods, and offers the possibility to evaluate signifi-
cant differences between two measurements. 
To date, there are over twenty international guide-
lines issued by national standardization institutes, 
professional associations and accreditation bod-
ies, which explain methods for the estimation and 
expression of measurement uncertainty (2-13). Un-
fortunately, all of these guidelines propose differ-
ent approaches in measurement uncertainty esti-
mation, different components for uncertainty 
budget and different equations in measurement 
uncertainty calculation. There is no agreement be-
tween experts on international level on how to es-
timate and express the measurement uncertainty. 
Most of the published guidelines include coeffi-
cient of variation of repeated measurements, bias 
and uncertainty of calibrator.
However, in laboratories the data on bias and un-
certainty of calibrator are often not known or not 
easily available. The main reason for that is lack of 
use of certified reference materials (CRM) or prima-
ry standards. The quantity of the measurand in 
CRM is measured using a reference method cali-
brated to the primary standard. That is why CRM is 
used for bias estimation. Furthermore, if one 
would like to input uncertainty of calibrator in the 
uncertainty budget, that information should be 
available. However, in user specifications of cali-
brators, manufacturers do not provide informa-
tion on uncertainty of calibrator for the particular 
lot (14). Laboratories could obtain that information 
from the manufacturers on demand. Nevertheless, 
it should be emphasized that obtained data on 
uncertainty of calibrator is not lot specific. Since 
significant deviations between lots of the same 
calibrator could be noticed, it is clear that uncer-
tainty of calibrator could not be the same for each 
lot. Thus, each series of calibrator should be ac-
companied with the information on its uncertain-
ty.
Unfortunately, according to IVD Directive 98/79/
EC, information on uncertainty of calibrator for 
each lot is not obligatory for the manufacturer (15). 
Moreover, only a few manufacturers express un-
certainty of calibrator according to primary stand-
ard (or primary reference material) while most of 
them express it as an uncertainty according to 
master calibrator (Figure 1). It can be concluded 
that even if the manufacturer provides the infor-
mation on calibrator uncertainty we do not know 
according to which higher standard is that uncer-
tainty expressed.
Although EU Regulation 2017/746 (effective from 
May 5th, 2017) obliges manufacturers to provide 
information according to which higher standard is 
uncertainty of the calibrator expressed, full imple-
mentation of the Regulation is extended by 2022 
(16).
In order to be compliant with the international rec-
ommendations for measurement uncertainty esti-
mation, with respect to the above mentioned 
problems in trueness detection and uncertainty of 
calibrator, it is this working group’s opinion that 
uncertainty of measurement could be reliably esti-
mated from the internal quality data gained 
through appropriate period of time. The main pre-
sumption is that the control sample is commuta-
ble and the measurand has the same property as 
in the patient sample, respectively. In addition, if 
we are not sure about the commutability of the 
control sample, patient sample can be regarded as 
a convenient replacement with the condition that 
the measured value is near some point of interest 
(cut-off value or clinical decision limit values).
https://doi.org/10.11613/BM.2017.030502 Biochem Med (Zagreb) 2017;27(3):030502 
  3
Ćelap I. et al. Measurement uncertainty estimation recommendations
The period chosen for the data analysis should be 
long enough to cover a respectable number of 
changes of reagents, calibrators, control samples, 
analyser maintenances, working procedures, staff 
included in these procedures and environmental 
conditions.
This recommendation was done by the joint Work-
ing group for uncertainty of measurement of the 
Croatian Society of Medical Biochemistry and Lab-
oratory Medicine (CSMBLM) and Croatian Cham-
ber of Medical Biochemists (CCMB) based on avail-
able literature searched through the web sites of 
the international societies of laboratory medicine, 
i.e. the Australasian Association of Clinical Bio-
chemists (AACB), The Royal College of Pathologists 
of Australasia (RCPA), the International Federation 
for Clinical Chemistry and Laboratory Medicine 
(IFCC); standardization institutes, i.e. State Office 
for Metrology (BIPM), Clinical and Laboratory 
Standards Institute (CLSI); accreditation bodies 
(Ontario Laboratory Accreditation, American Asso-
ciation for Laboratory Accreditation (A2LA), Clini-
cal Pathology Accreditation (CPA UK), National Pa-
thology Accreditation Advisory Council (NPAAC), 
Singapore Accreditation Council (SAC) and pub-
lished papers (2-11,17-26). 
Using our own data, we evaluated all the suggest-
ed approaches in measurement uncertainty esti-
mation, and concluded that the most appropriate 
approach in laboratory medicine could be the one 
suggested by White et al. which is supported by 
Burnett and Westgard (17,24-27). This approach 
ensures that every medical laboratory could esti-
mate measurement uncertainty using its own data 
with minimal employee effort and without bur-
dening financial budget. 
This recommendation gives instructions on how 
to estimate uncertainty of measurement of quanti-
tative tests using CCMB recommended methods. 
The recommendation is intended to all medical 
biochemistry laboratories in Croatia, regardless of 
the level of health care they provide or accredita-
tion status. In such way, it will contribute to the 
uniformity of the measurement uncertainty esti-
mation and improvement of the test results com-
parability on the national level. 
How to use the estimated measurement 
uncertainty
The estimation of measurement uncertainty has 
its practical use in evaluation of laboratory test re-
sults. It is of utmost importance at the clinical out-
come cut-off levels, reference interval limits and 
significance of a difference between two measure-
ments. Further, estimated measurement uncer-
tainty obtained from long-term internal quality 
control (IQC) data is used for periodical assess-
ment of the analytical quality specifications set by 
laboratory. 
By knowing the measurement uncertainty (U), a 
specialist in laboratory medicine can correctly per-
ceive measurement result and provide reliable pa-
tient care and safety. Therefore, it is of utmost im-
portance that the measurement uncertainty esti-
Figure 1. Metrological traceability – property of a measured re-
sult whereby the result can be related to the reference through 
a documented unbroken chain of calibrators, each contributing 
to the measurement uncertainty (18). 
SI – International System of Units – unit of measurement - sca-
lar quantity which is conventionally defined and adopted with 
which every other quantity of the same kind can be compared 
to express the ratio of the second quantity to the first one as 
a number (18). PRM – primary reference material. Primary and 
secondary calibrators are the calibrators of the highest level in 
hierarchy and their uncertainty is the lowest in relation to the 
primary reference material. Lower level calibrators are made ac-
cording to primary and secondary calibrators. Master calibrator 
is a lower level calibrator in hierarchy and is used for working 
calibrator production by manufacturers. Working calibrators 
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mation is performed at the clinical decision limits 
or cut-off values. Following, the 1st Strategic Con-
ference of the European Federation of Clinical 
Chemistry and Laboratory Medicine (EFLM) held in 
Milan, defined a hierarchy of models which are to 
be used to set analytical performance specifica-
tions (28). The first model is based on the effect of 
analytical performance on clinical outcomes, the 
second is based on components of biological vari-
ation (BV) of the measurands, and the third model 
is based on state-of-the-art which relates to the 
highest level of analytical performance technically 
achievable. According to EFLM Task and Finish 
Group on Allocation of laboratory tests to differ-
ent models for performance specifications (TFG-
DM), the first model can be applied on measur-
ands which have central role in decision making 
and with established cut-off or decision limits (li-
pids, plasma glucose, albumin or troponins, etc.) 
(29). The BV model can be applied to most meas-
urands but with limitation and need to re-evaluate 
the validity of BV data (28-30). This model can be 
applied on measurands under strict homeostatic 
control and stable concentrations, or with measur-
ands where deviation from its stable concentra-
tion will not cause symptoms (plasma electrolytes 
and minerals, creatinine, urea, urate, haemoglobin, 
etc.). The state-of-the-art model is applied on 
measurands, which cannot be included in the two 
previously described models, and it covers mainly 
the measurands in urine. The significance of the 
result of the measurement uncertainty estimation 
can be assessed by comparing the result with the 
specifications defined according to models pro-
posed in the Milan conference, or with the total al-
lowable error (TEa) based on biological variation 
components as proposed by some authors (31-33). 
Further, we can use the criteria defined by some 
expert groups, or the criteria specified by manu-
facturers. The source of the criteria does not have 
to be the same for all laboratory tests but can be 
set based on available literature data and depend-
ing on the clinical use of the test (diagnostic, prog-
nostic, monitoring). 
Information on measurement uncertainty could 
produce corrective actions related to improve-
ment of analytical quality of the method. For ex-
ample, laboratory can replace a calibrator in use 
with a new one with lower measurement uncer-
tainty; ensure long-term use of the same lot of rea-
gents or more frequently calibrate the analyser. If 
the analytical quality specifications cannot be ob-
tained, despite corrective actions, laboratory can 
initiate replacement of the current method with 
the better one if such is available at the market.
The opinion of this working group is that the coef-
ficient of variation gained through laboratorieś  in-
ternal quality control data is sufficient for satisfy-
ing the minimal criteria for measurement uncer-
tainty estimation. The influences of other uncer-
tainties, such as those of pipettes used to dissolve 
calibrator or control material, or uncertainty of cal-
ibrator material is also reflected through the quali-
ty control results i.e. coefficient of variation, so 
they are not separately taken into account when 
estimating measurement uncertainty. Because of 
the reasons mentioned earlier about the CRM 
availability, this working group will not obligate 
laboratories to introduce bias into measurement 
uncertainty estimation. However, it is advisable for 
laboratories, which possess CRMs, to include bias 
into the equation for uncertainty of measurement 
estimation. 
As for the criteria limits, since the first model from 
Milan Conference requires clinical outcome stud-
ies which are still lacking, we recommend the use 
of quality specifications data for imprecision or, if 
bias is taken into account, for total error (TE) from 
one of the biological variation databases specifica-
tion (Ricos or other freely available databases). 
Namely, if our measurement uncertainty (U) is 
based only on coefficient of variation and is ex-
pressed with coverage factor of k = 2, then the ac-
ceptance criteria is 2 x imprecision (I, %) (Appendix 
1, Example 1). If we have a CRM and take bias into 
account, then the acceptance criteria is total error 
(TE, %) (Appendix 1, Example 2).
If the estimated measurement uncertainty does 
not meet the goal set, laboratory should analyse 
sources of variability within the measurement pro-
cess and implement the bottom up approach for 
measurement uncertainty estimation. 
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Measurement uncertainty estimation 
from verification data 
Before the implementation of a method into rou-
tine practice, measurement uncertainty should be 
estimated from the verification procedure data. 
The method performance verification includes 
precision data obtained according to CLSI EP15-A2 
protocol (34).
Quantity of the interest is measured in commercial 
control samples in triplicate, in five consecutive 
days. Repeatability (within run precision), repro-
ducibility (between run precision) and within-lab-
oratory precision (total laboratory precision) are 
calculated from the obtained results with equa-
tions presented in Appendix 2 (i.e. Eq. 5, Eq. 7, Eq. 
9, respectively). 
Within-laboratory precision represents standard 
measurement uncertainty (u). If expressed as coef-
ficient of variation, within-laboratory precision 
represents relative standard measurement uncer-
tainty (urel) (2). Depending on the desired level of 
confidence, the appropriate coverage factor (k) 
should be applied to give an expanded uncertain-
ty (U). For an approximately 95% level of confi-
dence k is 2. The equation for expanded relative 
measurement uncertainty (Urel) is: Urel = urel x 2 (2).
Measurement uncertainty estimation 
from long-term IQC data 
After a certain period of the method routine use 
and when sufficient number of IQC data is collect-
ed (i.e. 6 months) measurement uncertainty should 
be estimated again. Measurement uncertainty 
should be estimated after and every 6 months of 
the routine use for methods where IQC is carried 
out daily. If IQC is carried out less frequently than 
measurement uncertainty should be estimated 
every 12 months. 
Every laboratory should implement their own IQC 
frequency depending on the number of samples 
and/or batches and IQC policy. For example, for a 
small number of samples per batch IQC could be 
carried out once a day and for large number of 
samples and batches IQC could be carried out sev-
eral times per day (35). 
Further, every laboratory should pay attention to 
the selection of control samples, their storage and 
manipulation. To avoid variability in control mate-
rial preparation it is advisable to use ready-to-use 
control materials. Lyophilised control materials 
should be carefully prepared since the measure-
ment uncertainty of the pipette could contribute 
to variability of IQC data. Thus, pipettes should be 
regularly calibrated. Further critical parameters 
are: aliquoting, type of container, storage condi-
tions, sample freezing, homogeneity of thawed 
sample and manipulation with the sample accord-
ing to manufacturerś  recommendations. 
In cases where manipulation with the control sam-
ple differs from patient sample manipulation, esti-
mation of measurement uncertainty requires care-
ful investigation and, if needed, inclusion of other 
sources of variability (e.g. pipette). 
Laboratory should estimate yearly supply of the 
commercial control samples as a base for tenders 
to arrange sufficient quantity of the control mate-
rial with the same target value or the same pro-
duction series (at least 6 months). 
The long-term coefficient of variation represents 
urel, which multiplied with coverage factor gives 
Urel. Measurement result can be expressed togeth-
er with its measurement uncertainty expressed as: 
a) percentage (measured value ± Urel)
b) absolute value expressed in measurement unit 
(measured value ± U) (2).
Expanded measurement uncertainty (k = 2) repre-
sents 95% confidence interval (95% CI) of meas-
ured results. 
If expressed as percentage, the obtained measure-
ment uncertainty should be expressed as an inte-
ger (number without decimal places), while if 
measurement uncertainty is expressed as absolute 
value, it should be expressed in the same way as 
measured result (as an integer or with the same 
number of decimal places as measured result). For 
example, for HbA1c the measurement uncertainty 
can be expressed as 48 mmol/mol ± 3% or 48 
mmol/mol ± 1.44 mmol/mol (≈ 1 mmol/mol). 
Namely, if the measured result for HbA1c is 48 
mmol/mol and the estimated measurement un-
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certainty is ± 1 mmol/mol (95% CI) then we can as-
sume that true value of HbA1c is between 47 – 49 
mmol/mol with 95% probability. 
Measurement uncertainties should be estimated 
at all IQC levels near clinical decision limits.
If appropriate commercial control sample is not 
available (with values near clinical decision limit), 
patient control samples could be used. It should 
be emphasised that in such cases sample stability 
study must be assessed in order to cover the peri-
od in which that kind of control would be used. 
Examples of the measurement uncertainty estima-
tion are listed in Appendix 1. 
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1. REPEATABILITY
D = 5 days; N = 3 (replicates) Day 1 Day 2 Day 3 Day 4 Day 5
Glucose (mmol/L), measurement 1 5.43 5.29 5.40 5.30 5.17
Glucose (mmol/L), measurement 2 5.14 5.41 5.49 5.31 5.40
Glucose (mmol/L), measurement 3 5.06 5.40 5.44 5.14 5.25
Arithmetic mean (x) 5.21 5.37 5.44 5.25 5.27
Standard deviation, Sd
Sd1 Sd2 Sd3 Sd4 Sd5
0.19 0.07 0.05 0.10 0.12
Standard deviation, Sr (D=5) 0.12
CVr = (Sr / X) x 100 2.18%
2. BETWEEN RUN PRECISION
Grand mean, X 
(X = (x1 + x2 + x3 + x4 + x5) / D)
5.31
Between run precision, Sb 0.09
CVb = (Sb / X) x 100 1.79%
3. WITHIN-LABORATORY PRECISION
Within-laboratory precision, Sl 0.16
CVl = (Sl / X) x 100 = urel 2.52%
4. UNCERTAINTY OF MEASUREMENT 
Urel = (2 x urel) 5.04%  5%
The acceptance of the result is verified through comparison with the 2 x I (2.8%) = 5.6%.
example 1. Measurement uncertainty estimation from verification data
Appendix 1. Examples of measurement uncertainty estimation
1. TRUENESS
Target value from manufacturer, Xref 5.40
B = ( (X – Xref) / Xref) 0.017
Brel = ( (X – Xref) / Xref) x 100 1.7 %
2. UNCERTAINTY OF MEASUREMENT
Urel = 2 x Brel + urel
2 2 5.88%  6%
The acceptance of the result is verified trough comparison with the TE value (6.96%). 
CRM - certified reference materials.
example 2. Measurement uncertainty estimation including bias (if CRM is used)
https://doi.org/10.11613/BM.2017.030502 Biochem Med (Zagreb) 2017;27(3):030502 
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3a. Measurement uncertainty estimation from long term IQC data without control lot change within 6 months
Control sample Level 1
Number of lots used 1
Frequency of IQC 3 x day
Period January 1 – June 30
Number of data, N 540
Arithmetic mean, XIQC 5.68 mmol/L
Standard deviation, SIQC = 0.20 mmol/L
Coefficient of variation, CVIQC =          x 100 3.53%
Relative standard measurement uncertainty, urel = CVIQC 3.53%
Expanded relative measurement uncertainty, Urel = 2 x urel 7.07  7%
3b. Measurement uncertainty estimation from seven lots of control samples
Control sample Level 3
Number of lots 7
Frequency of IQC 1 x day
Period January 1 – June 30
Number of data, N 132
LOT 1 LOT 2 LOT 3 LOT 4 LOT 5 LOT 6 LOT 7
N 17 29 21 27 9 17 12
x, g/L 155 149 150 152 148 153 152
S, g/L 1.46 2.00 0.98 1.35 0.71 1.71 1.31
CV, % 0.94 1.34 0.66 0.89 0.48 1.12 0.86
Calculation of the combined coefficient of variation from coefficient of variations of all lots:
n
(CV1 + CV2 +... + CVn)
2 2 2 (0,942 + 1,342 + 0,662 + 0,892 + 0,482 + 1,122 + 0,862)
= =
7
0.94 = urelCVIQC = 
Urel = 2 x urel = 2 x 0.94 =1.88%  2%
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Term (abbreviation) Equation Equation designation
Arithmetic mean (x) x1 + x2 + xn
nx =
Eq. 1
Standard deviation (S) ∑(x – x)
2
n – 1S =
Eq. 2
Coefficient of variation (CV) CV = x 100x
S
Eq. 3
Grand mean (X) X = 
D
(x–1 + x–2 + x–3 + x–4 + x–5) Eq. 4
Repeatability 
(within run precision) (Sr)
Sr = 
5
Sd1 + Sd2 + Sd3 + Sd4 + Sd5
2 2 2 2 2
Eq. 5
Coefficient of variation 
(from repeatability) (CVr)
CVr = x 100X
Sr
Eq. 6
Between run precision (Sb)
∑d=1(xd – x)2
D – 1Sb =
D
Eq. 7
Coefficient of variation 
(from between run precision) (CVb)




(total laboratory precision) (Sl)
n – 1Sl = × Sr + Sbn
2 2 Eq. 9
Coefficient of variation 
(from within-laboratory precision) (CVl)
CVl = x 100X
Sl
Eq. 10
Standard measurement uncertainty 
(from verification data) (u) u = Sl Eq. 11
Expanded measurement uncertainty 
(from verification data) (U) U = k × Sl Eq. 12
Trueness 
(absolute) (B)






x 100 Eq. 14
Expanded combined relative measurement 
uncertainty (Uc rel)
Uc rel = k x Brel + urel
2 2 Eq. 15
Combined coefficient of variation 
several series (CVIQC) n
(CV1 + CV2 +... + CVn)
2 2 2
CVIQC = Eq. 16
Expanded relative measurement uncertainty 
from IQC data (Urel)
Urel = k x CVIQC Eq. 17
Expanded combined measurement 
uncertainty (Uc)
Uc = k x B + u
2 2 Eq. 18
Expanded combined measurement uncertainty 
(common equation)
Uc = k x u1 + u2 + u3 + ... un
2 2 2 2 Eq. 19
N = number of replicates. d = day. D = total number of days. k = coverage factor. IQC = internal quality control.
Appendix 2. Definition of terms and equations
